ClinicaliQ Podcasts
Three series covering the guidelines, drug classes, and practical prescribing topics that matter most to UK healthcare professionals.
Three Series. One Platform.
Every episode is produced with a practising pharmaceutical physician, grounded in current UK and European guidance.
In-depth discussions of the latest NICE, ESC, and other major clinical guidelines — unpacking what's changed and what it means for your practice.
Deep-dive episodes on the most clinically significant drug classes — mechanism of action, evidence base, patient selection, monitoring, and common pitfalls.
Short, practical episodes on everyday prescribing challenges — the bread-and-butter topics every clinician needs to get right, every time.
4 Episodes Available Now
Organised by series. Each episode earns CPD credit.
GLP-1 Agonists: Semaglutide, Tirzepatide and the Cardiovascular Revolution
GLP-1 agonists have transformed the treatment of type 2 diabetes and obesity. In this episode, Dr Anzal Qurbain explains how they work, the landmark cardiovascular trials that changed prescribing practice, the significant weight loss data, and the key safety considerations every prescriber needs to know.
SGLT2 Inhibitors: From Glycaemia to Heart Failure and Chronic Kidney Disease
SGLT2 inhibitors started as diabetes drugs and became some of the most important medicines in cardiology and nephrology. Dr Anzal Qurbain covers the mechanism, the landmark DAPA-HF, EMPEROR-Reduced, a
JAK Inhibitors: Updated Safety Signals, Patient Selection and Post-ORAL Surveillance
JAK inhibitors have transformed inflammatory diseases from rheumatoid arthritis to eczema — but post-marketing safety data has reshaped how we use them. Dr Anzal Qurbain unpacks the updated MHRA and E